BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

232 related articles for article (PubMed ID: 17184589)

  • 1. Curcumin synergistically augments bcr/abl phosphorothioate antisense oligonucleotides to inhibit growth of chronic myelogenous leukemia cells.
    Zhang KZ; Xu JH; Huang XW; Wu LX; Su Y; Chen YZ
    Acta Pharmacol Sin; 2007 Jan; 28(1):105-10. PubMed ID: 17184589
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Down-regulation of p210(bcr/abl) by curcumin involves disrupting molecular chaperone functions of Hsp90.
    Wu LX; Xu JH; Huang XW; Zhang KZ; Wen CX; Chen YZ
    Acta Pharmacol Sin; 2006 Jun; 27(6):694-9. PubMed ID: 16723087
    [TBL] [Abstract][Full Text] [Related]  

  • 3. [Synergism of As2S2 and STI 571 in inducing apoptosis of K562 cells].
    Li JE; Sun GL; Wu YL; Wu WL
    Zhonghua Xue Ye Xue Za Zhi; 2003 Nov; 24(11):580-3. PubMed ID: 14720443
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Inhibitory effect of curcumin on proliferation of K562 cells involves down-regulation of p210(bcr/abl) initiated Ras signal transduction pathway.
    Wu LX; Xu JH; Wu GH; Chen YZ
    Acta Pharmacol Sin; 2003 Nov; 24(11):1155-60. PubMed ID: 14627502
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Imatinib (STI571)-mediated changes in glucose metabolism in human leukemia BCR-ABL-positive cells.
    Gottschalk S; Anderson N; Hainz C; Eckhardt SG; Serkova NJ
    Clin Cancer Res; 2004 Oct; 10(19):6661-8. PubMed ID: 15475456
    [TBL] [Abstract][Full Text] [Related]  

  • 6. [The mechanism of apoptosis of chronic myeloid leukemia cells induced by the novel p210 bcr/abl inhibitor berbamine].
    Sun JR; Zhang XH; He ZW; Gu Y; Yu YZ; Fang YM; Lü QH; Dong QH; Xu RZ
    Zhonghua Yi Xue Za Zhi; 2006 Aug; 86(32):2246-51. PubMed ID: 17064567
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Inhibition of phosphotyrosine phosphatase 1B causes resistance in BCR-ABL-positive leukemia cells to the ABL kinase inhibitor STI571.
    Koyama N; Koschmieder S; Tyagi S; Portero-Robles I; Chromic J; Myloch S; Nürnberger H; Rossmanith T; Hofmann WK; Hoelzer D; Ottmann OG
    Clin Cancer Res; 2006 Apr; 12(7 Pt 1):2025-31. PubMed ID: 16609011
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Trichosanthin down-regulated p210Bcr-Abl and enhanced imatinib-induced growth arrest in chronic myelogenous leukemia cell line K562.
    Zhang K; Xu J; Huang X; Wu L; Wen C; Hu Y; Su Y; Chen Y; Zhang Z
    Cancer Chemother Pharmacol; 2007 Sep; 60(4):581-7. PubMed ID: 17435997
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [Overexpression of Shp-2 is associated with the unlimited growth and apoptosis resistance of p210 bcr-abl-mediated chronic myeloid leukemia].
    Zhu XZ; Yu YZ; Fang YM; Liang Y; Lü QH; Xu RZ
    Zhonghua Yi Xue Za Zhi; 2005 Jul; 85(27):1903-6. PubMed ID: 16255985
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Celecoxib and curcumin synergistically inhibit the growth of colorectal cancer cells.
    Lev-Ari S; Strier L; Kazanov D; Madar-Shapiro L; Dvory-Sobol H; Pinchuk I; Marian B; Lichtenberg D; Arber N
    Clin Cancer Res; 2005 Sep; 11(18):6738-44. PubMed ID: 16166455
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Inhibition of chronic myelogenous leukemia cells harboring a BCR-ABL B3A2 junction by antisense oligonucleotides targeted at the B2A2 junction.
    Mahon FX; Ripoche J; Pigeonnier V; Jazwiec B; Pigneux A; Moreau JF; Reiffers J
    Exp Hematol; 1995 Dec; 23(14):1606-11. PubMed ID: 8542954
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [Effect of specific siRNA targeting against bcr-abl chimeric gene on chronic myelogenous leukemia cells].
    Wang S; Chai YB; Liu F; Zhang XY; Jia W; Xie X; Yu WQ; Shang ZC; Jin BQ; Sun BZ
    Zhonghua Yi Xue Za Zhi; 2005 Jan; 85(3):198-202. PubMed ID: 15854468
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Cotreatment with apicidin overcomes TRAIL resistance via inhibition of Bcr-Abl signaling pathway in K562 leukemia cells.
    Park SJ; Kim MJ; Kim HB; Sohn HY; Bae JH; Kang CD; Kim SH
    Exp Cell Res; 2009 Jul; 315(11):1809-18. PubMed ID: 19268463
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [Effect on bcr-abl signaling pathway and the mechanisms of apoptosis induction by meisoindigo in K562 cells].
    Liu BC; Xiao ZJ
    Zhonghua Xue Ye Xue Za Zhi; 2008 Dec; 29(12):815-8. PubMed ID: 19176035
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Apoptotic effect of As2S2 on K562 cells and its mechanism.
    Li JE; Wu WL; Wang ZY; Sun GL
    Acta Pharmacol Sin; 2002 Nov; 23(11):991-6. PubMed ID: 12421474
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The multikinase inhibitor sorafenib induces apoptosis in highly imatinib mesylate-resistant bcr/abl+ human leukemia cells in association with signal transducer and activator of transcription 5 inhibition and myeloid cell leukemia-1 down-regulation.
    Rahmani M; Nguyen TK; Dent P; Grant S
    Mol Pharmacol; 2007 Sep; 72(3):788-95. PubMed ID: 17595328
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [Inhibition of apoptosis by bcr-abl fusion gene in K562 cells].
    Wang C; Sun B; Yuan Y
    Zhonghua Zhong Liu Za Zhi; 1998 Sep; 20(5):340-1. PubMed ID: 10921025
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Effect of curcumin on nuclear factor kappaB signaling pathways in human chronic myelogenous K562 leukemia cells.
    Reuter S; Charlet J; Juncker T; Teiten MH; Dicato M; Diederich M
    Ann N Y Acad Sci; 2009 Aug; 1171():436-47. PubMed ID: 19723087
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [Effect of hydroxyurea combined with interferon-alpha on growth and apoptosis-related oncogene expression of K562 cells].
    Chen H; Luo Z; Luo S
    Zhonghua Yi Xue Za Zhi; 2000 Aug; 80(8):606-9. PubMed ID: 11798827
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [Mechanism related to inhibition of leukemia K562 cells by berbamine].
    WEI YL; XU L; ZHAO XY
    Zhejiang Da Xue Xue Bao Yi Xue Ban; 2009 Jul; 38(4):387-91. PubMed ID: 19693977
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.